news

Novel enterocyte-like cells developed by researchers from stem cells

A team has developed enterocyte-like cells from hiPSCs, which can be used to study the absorption of novel oral drugs.

Enterocytes in intestines

Scientists have developed novel enterocyte-like cells from human-induced pluripotent stem cells (hiPSCs), which can differentiate into any type of cell when provided with the right growth factors. The cells were developed at the Tokyo Institute of Technology and the University of Tokyo, both Japan, along with their collaborators. 

According to the researchers, enterocytes line the epithelium of the small intestine and are the sites of absorption and metabolism of most orally consumed medications. For this reason, studies on the absorption of novel oral drugs rely on in vitro or animal models to accurately recreate the environment of the small intestine.

Currently, scientists widely use the human colon cancer cell line Caco-2 as a model of the intestinal epithelium. However, this has its drawbacks: Caco-2 cells have been derived from the colon; therefore, they more closely resemble the colon than the small intestine. These cells do not express cytochrome P450 3A4 (CYP3A4), a protein critical for drug metabolism that is abundantly expressed in the small intestine. Moreover, Caco-2 cells tend to show high cell-line to cell-line variations.

To tackle these problems, the team developed novel enterocyte-like cells from hiPSCs, which can differentiate into any type of cell when given the right growth factors.

By modifying a procedure that they previously used on human embryonic stem cells, the scientists initially grew cells that resemble the early stages of small intestine cells, called intestinal progenitor cells. Then, they cultured these progenitor cells on a collagen vitrigel membrane (CVM). They treated the progenitor cells with a maturation medium containing 6-bromoindirubin-3′-oxime, dimethyl sulfoxide, dexamethasone and activated vitamin D3. Their efforts resulted in the development of enterocyte-like cells that closely resembled actual enterocytes, expressing efflux transporter proteins regulating drug absorption as well as CYP3A4, which Caco-2 cells lack.

Associate Professor Nobuaki Shiraki, at Tokyo Institute of Technology, and one of the corresponding authors of this study, said: “We established an efficient culture procedure for generating enterocyte-like cells from hiPSCs by culturing the hiPSC-derived endoderm or intestine progenitor cells on CVM.”

The scientists claim that these first-of-their-kind enterocyte-like cells can be used as an in vitro model of the small intestine for evaluating the intestinal absorption of drugs in humans.

Professor Shoen Kume, at Tokyo Institute of Technology, and co-corresponding author of the study, commented: “The hiPSC-derived enterocyte-like cells established in this study could be used for the quantitative prediction of the intestinal absorption of drugs in humans under special occasions such as alteration of the functions of transporters/metabolic enzymes by drug-drug interactions as well as normal conditions.”

The study was published in Stem Cell Reports

Send this to a friend